HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
F0670 Akt3 Rabbit mAb Oct 09 2024
F0616 α Actinin (C22H3) Rabbit mAb Actinin alpha,alpha Actinin/ACTN1,alpha-Actinin,α-Actinin Oct 09 2024
F0745 PKC ζ (J7H1) Rabbit mAb PKC zeta,PKC ζ,PKCζ Oct 09 2024
F2199 α Actinin 1/ACTN1 (C8H2) Rabbit mAb Actinin alpha,alpha Actinin/ACTN1,alpha-Actinin,α-Actinin Oct 09 2024
F2225 Angiotensin II Type 2 Receptor Rabbit mAb AGTR-2,Angiotensin II Type 2 Receptor Oct 09 2024
F2229 Phospho-Histone H3 (Ser 10/ Thr 11) Rabbit mAb Oct 09 2024
F2231 Mitofilin Rabbit mAb Oct 09 2024
F2438 ACOX1/AOX Rabbit mAb ACOX1,ACOX1/AOX Oct 09 2024
F2456 Angiotensin Converting Enzyme 1 Rabbit mAb Oct 09 2024
F2461 HMGCS2 Rabbit mAb Oct 09 2024
E1967 ORIC-944 ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit. It exhibits anti-tumor activity in vivo prostate cancer models. Oct 07 2024
E4947 Estrone sulfate sodium Estrone sulfate (Estrone 3-sulfate sodium salt, Premarin), an inactive form of estrogen, serves as a major circulating estrogen in the plasma. It is converted into the active form, estrone (E1), through the action of steroid sulfatase (STS. Estrone sulfate is commonly used in breast cancer research. Oct 07 2024
E4692 THZ-P1-2 THZ-P1-2 is an inhibitor of PI5P4K, which covalently binds to cysteines on a disordered loop in PI5P4Kα/β/γ. It inhibits PI5P4Kα kinase activity with an IC50 of 190 nM and disrupts autophagy by impairing autophagosome clearance and increasing TFEB nuclear localization. Oct 07 2024
E1831 FX-909 FX-909 is an orally available inverse agonist and inhibitor of the transcription factor (TF) peroxisome proliferator activated receptor gamma (PPARG, PPARγ) ), which exhibits anti-tumor activity in vivo. Oct 07 2024
E4958 cis-Bac430 Cis-Bac430 plays a role in mediating the movement of anti-tumor CD8+cells from the periphery to the tumor site,thus enhancing the anti-tumor effect of an immune checkpoint inhibitor. Sep 29 2024
E4886 HS-10296 hydrochloride HS-10296 hydrochloride(Almonertinib (hydrochloride), HS-10296 HCl) is an irreversible, third-generation inhibitor of EGFR tyrosine kinase that demonstrates high selectivity for EGFR-sensitizing mutations, T790M resistance mutation. It exhibits inhibitory activity against T790M, T790M/L858R, and T790M/Del19, with IC50 of 0.37 nM, 0.29 nM, and 0.21 nM, respectively. It also exhibits anti-tumor activity. Sep 28 2024
E1973 R16 R16(NSC29869, Nrf2-IN-3) is an inhibitor of NRF2 (nuclear factor erythroid 2-related factor 2) that selectively binds KEAP1 mutants and restores their NRF2-inhibitory function by repairing the disrupted KEAP1/NRF2 interactions. It significantly enhances the sensitivity of KEAP1-mutated tumor cells to cisplatin and gefitinib. Sep 28 2024
E1349 TNG908 TNG908 is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model. Sep 28 2024
E1842 Palazestrant Palazestrant(OP-1250) is an orally bioavailable complete antagonist of estrogen receptor (ER) that blocks ER activity. It exhibits antiproliferative and antitumor activity in ER-positive (ER+) breast cancer models. Sep 28 2024
E4893 Flecainide hydrochloride Flecainide hydrochloride, an antiarrhythmic drug, is a blocker of hydrophilic sodium channels with a pKa of 9.3. At pH 7.4. It also inhibits the ryanodine receptor (RyR2), reducing spontaneous calcium release from the sarcoplasmic reticulum. Sep 28 2024